Articles tagged with Nucleocapsids
A new study reveals that the SARS-CoV-2 nucleocapsid protein can spread between cells, triggering an immune response that mistakenly targets healthy cells. The researchers found that a commonly used anticoagulant, enoxaparin, can block this harmful interaction, potentially offering a new avenue for treatment.
Researchers at Kyoto University have captured the first high-resolution structure of Ebola's nucleocapsid using single-particle cryo-electron microscopy. This visualization reveals sophisticated interactions between structural components, including VP24 and NP proteins, which govern virus assembly, RNA synthesis, and transport.
The novel coronavirus SARS-CoV-2 has an enzyme that counteracts the innate defense mechanism against viruses, allowing it to evade the innate immune system and become more infectious. Understanding this mechanism may lead to the development of new antiviral drugs and treatments.
SARS-CoV-2's nucleocapsid protein (N) uses human body temperature to replicate, binding to RNA motifs at specific spatial folds. The study reveals new functions and potential targets for antiviral drugs.
Researchers develop eRapid sensor technology to detect SARS-CoV-2 antibodies, enabling fast and multiplexed testing at the point-of-care. The device distinguishes between antibody types targeting different viral proteins with high sensitivity and specificity.
Researchers used virus-like particles to identify mutations in Omicron that make it more infectious and escape antibodies. The study found that mutations in the nucleocapsid protein are crucial for enhancing spread, highlighting potential new vaccine targets.
The SARS-Arena program identifies conserved peptides in the SARS-CoV-2 virus that could be used to develop vaccines. The peptides are part of the nucleocapsid protein, which is highly expressed upon infection and highly immunogenic.
A multicenter study found mutations in the SARS-CoV-2 N protein associated with increased viral loads and severe disease symptoms. The changes enabled the virus to hijack host cell translation machinery, leading to a life-threatening cytokine storm.
The investigational vaccine targets both the spike and nucleocapsid proteins, producing neutralizing antibodies and inducing T cell responses against SARS-CoV-2. COH04S1 is being studied in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers.
A UK study found that over a third of care home residents and a quarter of staff in England showed evidence of SARS-CoV-2 infection during the first two waves of the pandemic. The study also revealed that antibodies against the virus became undetectable in half of the population within eight months.
Research team discovered mRNA vaccines induce antibodies recognizing Spike and N protein fragments, potentially leading to misclassified breakthrough infections. The study suggests using multiple viral antigens for accurate detection of vaccine effectiveness.
Researchers found that asymptomatic patients may not produce significant IgG antibodies, but rather a different kind of antibody count that can indicate disease severity. The study suggests using the ratio of these two counts as a marker to determine if a person has had COVID-19.
A team of researchers used Stampede2 and Bridges simulations to analyze the stability of the Ebola virus's nucleocapsid, a protein shell that protects its genetic material. The study found that RNA helps stabilize the nucleocapsid through electrostatic interactions with its nucleoproteins, providing potential targets for new therapeutics.
A computational study of Ebola's nucleocapsid reveals how ssRNA encapsulation stabilizes the virus, maintaining its structural integrity. The model includes all atoms and ions essential for the helical assembly, providing insights into the virus's ability to infect and replicate.
The study reveals structural features of the Ebola nucleocapsid, a promising therapeutic target for destabilizing the virus and knocking it out with antivirals. The researchers used supercomputers to simulate the inner workings of Ebola, observing the way molecules move to carry out their functions.
The study reveals a unique RNA binding pocket in SARS-CoV-2 nucleocapsid protein, which could guide the design of novel antiviral agents. The crystal structure provides atomic resolution features that may lead to the development of specific targeting sites for SARS-CoV-2.
A case series examined SARS-CoV-2 presence in ocular tissues of a patient with previous COVID-19. The study found the virus in ocular tissues, highlighting its potential role in long-term complications.
Researchers have discovered a target for Schmallenberg virus treatment by identifying the nucleocapsid protein as a key building block that can be blocked to kill the virus. The study, published in Nucleic Acids Research, provides insight into the structure and function of the protein.
Scientists at Scripps Research Institute developed a new chemical-screening method to find anti-HIV compounds targeting the nucleocapsid protein. The method yielded two effective and safe inhibitors with demonstrated anti-HIV activity in cell culture tests, offering hope for the development of new HIV treatments.
Scientists investigate key clues behind coronavirus illness, including its ability to evade the immune system. They aim to design better vaccines and treatments for diseases like pandemic flu. By understanding virus-host interactions, researchers hope to refine their approach to combating emerging public health threats.